From precision medicine to immunotherapy, from novel targeted drugs to cell therapy, China has formed unique strengths in several cancer treatment fields. As a platform connecting international patients with China’s medical resources, DengYueMed closely follows…
In today’s increasingly complex pharmaceutical distribution system and highly active cross-border trade environment, counterfeit medicines have evolved from a national regulatory issue into a global public health and supply chain challenge. Both developed and developing…
As Semaglutide, Tirzepatide, and next-generation multi-target peptides like Retatrutide advance in development and commercialization, China’s peptide API industry is entering a new capacity expansion cycle. Currently, the China peptide API company landscape has gradually formed…
In the global pharmaceutical supply chain, drug transportation is no longer a simple logistics process. It has evolved into a highly specialized system focused on pharmaceutical stability management. Different dosage forms exhibit major differences in…
Spinal muscular atrophy (SMA) has seen continuous advances in spinal muscular atrophy research, clinical treatment, and long-term disease management in recent years. With the expanding use of disease-modifying therapies (DMTs) and the growing accumulation of…
Key Takeaways Understand the overall system: Modern cancer treatment in China has developed into a multidisciplinary, tiered system covering surgery, radiotherapy, systemic therapy, immunotherapy, and interventional procedures, while increasingly integrating precision medicine and emerging biologic…
A cancer diagnosis often brings many important questions.Which treatment option is most suitable? Which hospital has the right expertise? Should patients consider seeking further treatment overseas? In recent years, China has become an increasingly important…
Key Takeaways International Medical Services: More major Chinese hospitals have established international medical centers, with some holding JCI accreditation and offering English-speaking doctors and international patient services. Leading Medical Resources: Beijing, Shanghai, and Guangzhou are…
Since the beginning of 2026, the field of gastric cancer treatment has witnessed a major breakthrough. China’s National Medical Products Administration (NMPA) approved Retlirafusp Alfa Injection (SHR-1701) for first-line treatment of PD-L1-positive advanced gastric cancer…
From emergency medicines to chronic disease treatments, from anti-infectives to oncology therapies, instability in the global pharmaceutical supply chain is increasingly affecting healthcare systems worldwide. Between 2023 and 2025, drug shortages by country have worsened…
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as PD-1/PD-L1 and CTLA-4, and have become a cornerstone of modern oncology treatment. As one of the world’s most important markets…
Neuroscience (CNS) has long been regarded as one of the most challenging areas in the pharmaceutical industry, due to long development timelines, high failure rates, and complex disease mechanisms. ✨ In recent years, breakthroughs in…
